ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO065

MicroRNA671-5p Mediates Wnt/β-Catenin-Triggered Podocyte Injury by Targeting WT1

Session Information

Category: Glomerular

  • 1002 Glomerular: Basic/Experimental Pathology

Authors

  • Wang, Chunhong, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
  • Zhu, Wenjuan, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
  • Zhou, Lili, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
  • Liu, Youhua, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Background

Podocyte injury is the major pathological feature of many proteinuric kidney diseases. It has been shown that dysregulated activation of Wnt/β-catenin signaling in podocytes can lead to podocyte dedifferentiation and mesenchymal transition, causing impaired glomerular filtration and proteinuria. MicroRNAs (miRNAs) are a class of short non-coding RNAs, which regulates specific genes by targeting and fine-tuning their expression. To study whether miRNA is involved in mediating Wnt/β-catenin-triggered podocyte injury, we performed a comprehensive miRNA expression profiling and sought to identify the miRNAs that may play a crucial role in this process.

Results

Mouse podocytes were transiently transfected with expression vector encoding constitutively activated β-catenin (pDel-β-cat) or empty vector (pcDNA3). The differential expression of miRNAs was identified through a microarray analysis. Among several dozens of miRNAs which expression levels were altered after β-catenin activation, miR-671-5p was on the top of the list. Subsequent qRT-PCR confirmed that miR-671-5p was upregulated in cultured podocytes after β-catenin activation, as well as in the kidneys of proteinuric CKD. Bioinformatics analysis predicted that miRNA671-5p could target WT1 mRNA for degradation. Indeed, over-expression of miR671-5p induced down-regulation of WT1 protein and promoted podocyte injury, whereas it had no effect on the level of WT1 mRNA. Inhibition of miRNA671-5p mitigated podocyte injury caused by β-catenin activation. In mouse model of remnant kidney after 5/6 nephrectomy (5/6NX), miR671-5p was specifically up-regulated in glomerular podocytes, as shown by in situ hybridization. Furthermore, over-expression of miR671-5p in vivo promoted β-catenin activation, inhibited WT1, worsened podocyte injury and kidney fibrotic lesions in remnant kidney after 5/6NX.

Conclusion

These studies identify miR-671-5p as a novel mediator that plays a crucial role promoting podocyte injury through down-regulation of WT1. The study also provides new insights into the pathogenic mechanisms of Wnt/β-catenin in podocyte dysfunction. Therefore, miR-671-5p may be a potential therapeutic target for ameliorating podocyte injury in the proteinuric kidney diseases.

Funding

  • NIDDK Support